Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The worldwide prevalence of ADHD: a systematic review and metaregression analysis
Polanczyk, G., de Lima, M. S., Horta, B. L., Biederman, J., & Rohde, L. A. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.942 · Cited by 5,346 · cited 1×
“Sativex contains Δ9-THC and CBD in a 1:1 ratio, whereas the UK black market is currently dominated by high Δ9-THC Sinsemilla, with low Δ9-THC cannabis resin increasingly difficult to obtain (Potter et al., 2008).”
Wood, L., Egger, M., Gluud, L. L., Schulz, K. F., Jüni, P., Altman, D. G., Gluud, C., Martin, R. M., Wood, A. J. G., & Sterne, J. A. C. (2008) · BMJ · doi:10.1136/bmj.39465.451748.ad · Cited by 2,538
Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis
Simon, V., Czobor, P., Bálint, S., Mészáros, Á., & Bitter, I. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.048827 · Cited by 1,601
Devinsky, O., Cilio, M. R., Cross, H., Fernandez‐Ruiz, J., French, J., Hill, C., Katz, R., Di Marzo, V., Jutras‐Aswad, D., Notcutt, W. G., et al. (2014) · Epilepsia · doi:10.1111/epi.12631 · Cited by 1,000
Lee, S. S., Humphreys, K. L., Flory, K., Liu, R., & Glass, K. (2011) · Clinical Psychology Review · doi:10.1016/j.cpr.2011.01.006 · Cited by 875 · cited 1×
“One of the most common problems associated with ADHD is co-occurring substance abuse (Gudjonsson et al., 2012; Lee et al., 2011; Young and Thome, 2011).”
Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies
Michelson, D., Adler, L., Spencer, T., Reimherr, F. W., West, S. A., Allen, A. J., Kelsey, D., Wernicke, J., Dietrich, A., & Milton, D. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01671-2 · Cited by 790
Crean, R. D., Crane, N. A., & Mason, B. J. (2011) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e31820c23fa · Cited by 732
Di Forti, M., Marconi, A., Carra, E., Fraietta, S., Trotta, A., Bonomo, M., Bianconi, F., Gardner-Sood, P., O'Connor, J., Russo, M., et al. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)00117-5 · Cited by 588
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.11.1652 · Cited by 528
Nurmikko, T. J., Serpell, M. G., Hoggart, B., Toomey, P. J., Morlion, B. J., & Haines, D. (2007) · Pain · doi:10.1016/j.pain.2007.08.028 · Cited by 431 · cited 1×
“…of previous RCTs of Sativex in patients with Multiple Sclerosis; or who had neuropathic pain, which found efficacy of Sativex after 5–6 weeks (e.g. Nurmikko et al., 2007) (there are no studies of Sativex in adults with ADHD therefore trial duration could not be based on RCTs in this population).”
Adult attention-deficit hyperactivity disorder: key conceptual issues
Asherson, P., Buitelaar, J., Faraone, S. V., & Rohde, L. A. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30032-3 · Cited by 347
Self-citationMorgan, C. J. A., Schafer, G., Freeman, T. P., & Curran, H. V. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.077503 · Cited by 305 · cited 1×
“…of previous RCTs of Sativex in patients with Multiple Sclerosis; or who had neuropathic pain, which found efficacy of Sativex after 5–6 weeks (e.g. Nurmikko et al., 2007) (there are no studies of Sativex in adults with ADHD therefore trial duration could not be based on RCTs in this population).”
Bolea-Alamañac, B., Nutt, D. J., Adamou, M., Asherson, P., Bazire, S., Coghill, D., Heal, D., Müller, U., Nash, J., Santosh, P., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113519509 · Cited by 287
Self-citationCoghill, D. R., Seth, S., Pedroso, S., Usala, T., Currie, J., & Gagliano, A. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.10.005 · Cited by 271
Effects of Atomoxetine and Methylphenidate on Sleep in Children With ADHD
Sangal, R. B., Owens, J., Allen, A. J., Sutton, V., Schuh, K., & Kelsey, D. (2006) · Sleep · doi:10.1093/sleep/29.12.1573 · Cited by 214
Morgan, C. J. A., Gardener, C., Schafer, G., Swan, S., Demarchi, C., Freeman, T. P., Warrington, P., Rupasinghe, I., Ramoutar, A., Tan, N., et al. (2012) · Psychological Medicine · doi:10.1017/s0033291711001322 · Cited by 195 · cited 1×
“Studies in humans have suggested Δ9-THC to be responsible for the cognitive deficits induced by cannabis and that CBD may protect against these impairments (Englund et al., 2012; Morgan et al., 2012, 2010).”
Lisdahl, K. M., Wright, N. E., Medina-Kirchner, C., Maple, K. E., & Shollenbarger, S. (2014) · Current Addiction Reports · doi:10.1007/s40429-014-0019-6 · Cited by 160 · cited 1×
“Given that regular, long-term cannabis use has been associated with cognitive impairment (Lisdahl et al., 2014), it is also possible that the absence of negative effects on cognitive performance could be due to the short length of the study.”
Weisler, R. H., Biederman, J., Spencer, T. J., Wilens, T. E., Faraone, S. V., Chrisman, A. K., Read, S. C., & Tulloch, S. J. (2006) · CNS Spectrums · doi:10.1017/s1092852900013687 · Cited by 158 · cited 2×
“Weisler et al. (2006) in a placebo controlled RCT of stimulant medication in adults with ADHD, found, using the CAARS, an estimated reduction of 3–4 in the active compared with placebo group in symptoms of inattention and hyperactivity/impulsivity.”
Bijlenga, D., Jasperse, M., Gehlhaar, S. K., & Sandra Kooij, J. J. (2015) · European Psychiatry · doi:10.1016/j.eurpsy.2014.06.003 · Cited by 34
Cited by
Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan
Franke, B., Michelini, G., Asherson, P., Banaschewski, T., Bilbow, A., Buitelaar, J. K., Cormand, B., Faraone, S. V., Ginsberg, Y., Haavik, J., et al. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.08.001 · Cited by 643
Self-citationBlack, N., Stockings, E., Campbell, G., Tran, L. T., Zagic, D., Hall, W. D., Farrell, M., & Degenhardt, L. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30401-8 · Cited by 564
Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review
Sarris, J., Sinclair, J., Karamacoska, D., Davidson, M., & Firth, J. (2020) · BMC Psychiatry · doi:10.1186/s12888-019-2409-8 · Cited by 253
“One study was located, the “Experimental Medicine in ADHD-Cannabinoids” pilot RCT, using nabiximol (cannabinoid/terpene combination) oromucosal spray in 30 adults with ADHD for 6 weeks [108].”
MethodSafety, efficacy, and mechanisms of action of cannabinoids in neurological disorders
Friedman, D., French, J. A., & Maccarrone, M. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30032-8 · Cited by 203
Bilbao, A., & Spanagel, R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02459-1 · Cited by 181
Metadata
- Authors
- Cooper, R. E., Williams, E., Seegobin, S., Tye, C., Kuntsi, J., & Asherson, P.
- Venue
- European Neuropsychopharmacology
- Publisher
- Elsevier BV
- Published
- 2017-08
- Volume
- 27
- Issue
- 8
- Pages
- 795-808
- ISSN
- 0924-977X (ISSN-L)
- OpenAlex
- W2541740961
- Cited by
- 175
- References
- 19
- FWCI
- 8.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.